Barr must wait until patent expiry for US generic argatroban entry
This article was originally published in Scrip
Executive Summary
Barr Laboratories (part of Teva Pharmaceutical Industries) cannot launch its generic version of the direct thrombin inhibitor argatroban in the US until the expiry of the original product's formulation patent in mid-2014, an appeals court has ruled.